Outcomes of first-line long-acting octreotide treatment in non-functional, advanced gastroenteropancreatic neuroendocrine tumors

Saglam, Sezer; Hacisahinogullari, Hulya; Ozturk, Nakiye; Kapran, Yersu; Gulluoglu, Mine; Turkmen, Cüneyt; Adalet, Işık; Bilge, Ali; Balci, Numan

Outcomes of first-line long-acting octreotide treatment in non-functional, advanced gastroenteropancreatic neuroendocrine tumors

Atıf İçin Kopyala

Saglam S. , Hacisahinogullari H., Ozturk N., Kapran Y. , Gulluoglu M. , Turkmen C. , ...Daha Fazla

JOURNAL OF BUON, cilt.20, ss.1201-1205, 2015 (SCI İndekslerine Giren Dergi)

Cilt numarası: 20 Konu: 5
Basım Tarihi: 2015
Dergi Adı: JOURNAL OF BUON
Sayfa Sayıları: ss.1201-1205

Özet

Purpose: Benefits of somatostatin analogues have been mostly studied in mixed samples of patients including both functional and non-functional neuroendocrine tumors. This study aimed to examine the response of patients with non-functional metastatic or inoperable gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that received first-line treatment with the somatostatin analogue octreotide LAR.